Sesen Bio Inc

Sesen Bio — Q3 2020 Earnings Presentation

84 slides from Sesen Bio's earnings presentation, Nov 9, 2020

  1. Slide 1: 3Q 2020 Business Update

    3Q 2020 Business Update November 9, 2020 NASDAQ: SESN

  2. Slide 2: Forward-Looking Statements

    FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, clinical devel

  3. Slide 3: November 2020 Business Update

    NOVEMBER 2020 BUSINESS UPDATE 1. Differentiated MOA and clinical profile creates opportunity for best-in-class profile for Vicineum 2. Clear regulatory path forward for potential approval in US in 2021 and Europe in 2022 3. Significant global commercial opportunity; projected $1B - $3B peak revenue

  4. Slide 4: The Patient Journey in Bladder Cancer

    BLOOD IN URINE See PCP; therapeutic trial of antibiotics prescribed Still see blood in urine See blood in urine; THE PATIENT JOURNEY try different antibiotic Confusion and concern on problem Begin tests REFERRED TO Shock and UROLOGIST st CT Scan emotional Preparing for 1 TURBT struggle cancer treatm

  5. Slide 5: Corporate Highlights: Two Years of Execution Excellence

    Corporate Highlights: Two Years of Execution Excellence Successful Type C Initiated BLA submission Received PIP waiver Positive Pre-Submission meeting with FDA; from EMA meeting with EMA alignment on analytical comparability Positive 12-month Successful Type C Favorable market Announced preliminary

  6. Slide 6: Vicineum has a Highly Differentiated Clinical Profile

    Vicineum has a Highly Differentiated Clinical Profile Efficacy Data Safety Data 3-month response data Intravesical administration • CIS: 40% complete response rate (CRR) • Bladder wall serves protective function • Papillary: 71% recurrence-free rate • Preference of FDA* and most Urologists Durabilit

  7. Slide 7: Long-term relationship with the FDA shaped our programs

    Our long-term relationship with the FDA has allowed us to shape our nonclinical and clinical programs in alignment with the agency guidance 2018 FDA Guidance Vicineum Clinical Program • Conduct nonclinical studies to assess toxicity in animal models • Conduct nonclinical studies to demonstrate anti-

  8. Slide 8: Vicineum confidence interval above FDA success criteria

    Vicineum confidence interval above FDA success criteria based upon complete response of other agents in patients with Carcinoma in situ Keytruda 3-month CRR Vicineum 3-month CRR 60 60 U.S. Patients1 Overall3 Overall1 U.S. Patients3 53% 50 51% 50 51% 48% 40 41% 40 40% 41% 32% 31% 30 30 30% 29% CRR (%

  9. Slide 9: CMC comparability progress enables BLA completion in December 2020

    Positive progress in CMC comparability enables anticipated completion of BLA in December 2020 Module 1 Module 2 Module 3 Module 4 Module 5 General corporate Introduction to summary Drug substance 24 Non-clinical studies List of clinical studies information Quality overall summary • Manufacturer 30 N

  10. Slide 10: Forward-looking Timeline for Vicineum

    Forward-looking Timeline for Vicineum Positive progress in the US and Europe enables a clear regulatory path forward with the following anticipated milestones: US BLA completionFDA accepts file FDA approval Early commercial success 4Q 20 1Q 21 2Q 21 3Q 21 4Q 21 1Q 22 2Q 22 Europe MAA submission HTA/

  11. Slide 11: Completion of Vicineum BLA submission anticipated in December 2020

    Completion of Vicineum BLA submission anticipated in December 2020 Oncology Products Reviewed by FDA 2006 - 2015 Phase Probability of Approval Products at end of Phase I 5% Products at end of Phase II 8% Products at end of Phase III 33% Products with BLA Submission 82% As part of a comprehensive ana

  12. Slide 12: Large Global Commercial Opportunity

    Large Global Commercial Opportunity Substantial US opportunity and OUS potential of roughly two times the US • Projected peak revenue opportunity of $1B - $3B Anticipated virtuous cycle of advocacy across physicians, patients/caregivers, and payers to drive rapid uptake and strong growth after appro

  13. Slide 13: 2020 Market Research Results

    2020 Market Research Results High Prescribing Urologists Prefer Vicineum Profile Intent-to-Prescribe Key Attributes (Stated share of branded agents)* Extremely 10.0 90% 83% 9.0 8.6 80% 8.2 8.2 8.0 70% 7.0 6.2 60% 6.0 5.8 5.4 5.2 50% 5.0 40% Average Rating Average 4.0 % of patients 3.4 30% 3.0 17% 20

  14. Slide 14: NMIBC Therapeutics Have Been Plagued by Manufacturing Issues

    NMIBC Therapeutics Have Been Plagued by Manufacturing Issues No clear near-term resolution of the BCG shortage or the CMC issues for Adstiladrin Valstar was pulled from the market in 2002 due to impurities in the formulation. FDA Merck is constructing a new facility approval to re-introduce Valstar

  15. Slide 15: Vicineum End-to-End Supply Chain

    Vicineum End-to-End Supply Chain World-class manufacturing and distribution capabilities ensure execution excellence Our mission is to • Vicineum Drug Substance manufacturer • Vicineum Drug Product manufacturer • 3PL services (storage, ordering and • Shipment to accredited Urology accounts receivabl

  16. Slide 16: Highly Reliable Manufacturing Process for Vicineum

    Highly Reliable Manufacturing Process for Vicineum 2000 L E. coli Production Bioreactor Centrifugation (bulk solids removal) Clarification (MF for fine solids removal and UF/DF for buffer exchange) Cell Bank Shake flask 5 Column Purification DP Fill Finish (7 mL @ 5mg/mL) 1: Q-Sepharose FF 2: Ni2+ I

  17. Slide 17: Positive US and European Regulatory CMC Feedback

    Positive US and European Regulatory CMC Feedback Our analytical comparability plan is aligned with global standards issued by the ICH and feedback from the FDA and EMA FDA Feedback May 2019 Type C and December 2019 Type B pre-BLA meeting: FDA Accepts Analytical Comparability Plan • Reached alignment

  18. Slide 18: Commercial Manufacturing Strategy Based on Demonstrating Comparability

    Commercial Manufacturing Strategy Based on Demonstrating Comparability We aligned with the FDA on assessing analytical comparability in support of approval for commercial manufacturing at our CMOs Clinical Supply Commercial Supply Drug Substance Sesen FUJIFILM Diosynth Biotechnologies (CMO) Drug Pro

  19. Slide 19: Meaningful Progress on Demonstrating Comparability

    Meaningful Progress on Demonstrating Comparability We have maintained high-quality manufacturing standards through the tech transfer process Sesen FUJIFILM Diosynth Biotechnologies Test Phase III PPQ1 PPQ2 PPQ3 Appearance pH Identity Concentration Polysorbate 80 Purity Charge Variants Potency Bindin

  20. Slide 20: Extensive Biophysical Characterization Supports Comparability

    Extensive Biophysical Characterization Supports Comparability Structural characteristics of biologics impart biological function FUJIFILM Diosynth Sesen Highly Biotechnologies (Phase III Average) Comparable Test (PPQ Average) Analytical Ultracentrifugation 4.25 4.24 (S-value) 272.9 nm 272.5 nm Circu

  21. Slide 21: Forced Degradation Studies in Support of Comparability

    Forced Degradation Studies in Support of Comparability Clinical and commercial material display highly similar degradation profiles, providing strong support for comparability 25°C Forced Degradation Study 120 The Comparability plan includes: 100 1. High temperature (25°C) 80 2. pH 7.5 and pH 10 60

  22. Slide 22: Long-term Stability in Support of Comparability

    Long-term Stability in Support of Comparability Based on available stability data, clinical and commercial material display comparable stability profiles at -20°C, providing strong support for comparability and justification for a robust commercial shelf life 102 At our CMC pre-BLA meeting, we reach

  23. Slide 23: Key Activities to Complete Module 3

    Key Activities to Complete Module 3 Finalize the statistical analysis of in-process and release testing data from the PPQ campaigns Finalize the writing of all validation documents required for Module 3 Perform quality control review of Module 3 and publish into FDA submission format We anticipate M

  24. Slide 24: Forecast Simulation Model Key Assumptions

    Forecast Simulation Model Key Assumptions US and OUS US Inputs OUS Inputs Output High-risk NMIBC patients unresponsive to BCG Prevalence (relative to US) Estimated peak market share Peak Revenue Opportunity for Vicineum: Approximate year 1 doses received $1B - $3B Price (relative to US) Anticipated

  25. Slide 25: OUS opportunity roughly double the US

    We estimate the OUS opportunity for Vicineum is roughly double the US Peak Revenue Opportunity for Vicineum Geography (captures 80% of variance) Europe $450M - $1,125M US $423M - $942M China $155M - $418M MENA $158M - $420M Rest of Asia (incl. Japan) $109M - $282M Latin America $51M - $150M Canada $

  26. Slide 26: 3Q 2020 Financial Highlights

    3Q 2020 Financial Highlights 3Q 2020 Net Proceeds Qilu upfront $10.0M ATM $ 8.2M Total $18.2M $14M Cash Used in Operations in 3Q • Tech transfer/manufacturing scale-up • Regulatory support of BLA in US • Regulatory support of MAA in Europe $42M in cash and cash equivalents • No outstanding debt ATM

  27. Slide 27: 3Q 2020 Flux Analysis

    3Q 2020 Flux Analysis Strengthening the Balance Sheet while Minimizing Dilution June 30 Sept 30 Change Cash and cash equivalents $38M $42M +10% Shares outstanding 117M 124M +6% Market cap $84M $173M +106% 27

  28. Slide 28: Sesen Bio Highlights

    SESEN BIO HIGHLIGHTS 1. Differentiated MOA and clinical profile creates opportunity for best-in-class profile for Vicineum 2. Clear regulatory path forward for potential approval in US in 2021 and Europe in 2022 3. Significant global commercial opportunity; projected $1B - $3B peak revenue for Vicin

  29. Slide 29: Thank You

    THANK YOU

  30. Slide 30: Talented and Experienced Leadership Team

    Talented and Experienced Leadership Team Prepared for Commercial Launch Senior Management Board of Directors Omar Rifi Thomas Cannell, DVM Jay Duker, M.D. Vice President, Business Development President, CEO and Director Chair of the Board of Directors and Alliance Management Monica Forbes Louise Ste

  31. Slide 31: Appendix - Table of Contents

    Appendix - Table of Contents Section Slide number Unmet Medical Need 32-35 Dual Mechanism of Action 36-39 Regulatory 40-42 Clinical Data 43-63 Commercial Opportunity 64-80 Manufacturing & Supply Chain 81-82 Intellectual Property 83-84 For Investor Purposes Only 31

  32. Slide 32: Appendix: Unmet Medical Need

    Appendix Unmet Medical Need 32

  33. Slide 33: Significant Unmet Medical Need in NMIBC

    Significant Unmet Medical Need in NMIBC ~440,000 Bladder cancer is the 6th most prevalent cancer in the US, of which 75%-85% is NMIBC2,3 new cases each year globally1 Bladder cancer is the most expensive cancer to treat in the US with projected costs of ~$6B by 20204 One of the worst patient experie

  34. Slide 34: Vicineum is cystectomy-sparing

    Our Phase III data suggests Vicineum is cystectomy-sparing by significantly delaying or avoiding cystectomy for patients Your Bladder: An Essential Organ Radical Cystectomy: Life-Altering Surgery Self-controlled storage organ in Often a 10 hour or longer surgery the body In women, removal of the ent

  35. Slide 35: Significant Unmet Need in China

    There is a Significant Unmet Need in China Bladder Cancer is the 13th Most >300M Adult Smokers in China5 Common Cancer in China1 • Largest smoking population in the • 1.6-1.7 times the incidence vs. the US2 world • Case fatality rate is 41% vs. 22.5% in • Smoking is the most important risk the US3 f

  36. Slide 36: Appendix: Dual Mechanism of Action

    Appendix Dual Mechanism of Action 36

  37. Slide 37: Vicineum has a Highly Differentiated Mechanism of Action

    Vicineum has a Highly Differentiated Mechanism of Action Mechanism 1: Mechanism 2: Kills cell directly Activates immune system Vicineum selectively targets EpCAM on T cells recognize neoantigen cancer cells while and kill cancer cells generally leaving healthy cells alone Vicineum causes immunogenic

  38. Slide 38: Vicineum Dual Mechanism of Action

    Vicineum is Highly Differentiated and has a Dual Mechanism of Action • Fusion protein consisting of an antibody fragment and a cytotoxic payload • Small size facilitates tumor penetration and greater drug delivery • Selectively targets cancer cells while generally sparing healthy cells • Inhibits pr

  39. Slide 39: Evidence of activation of patients' immune systems

    Pre-clinical and Phase I Trial in SCCHN shows evidence of activation of patients’ immune systems Pre-Clinical Evidence Clinical Evidence (as seen in Phase I) After 4wks on Pre-treatment Immunogenic Cell Death (ICD) treatment • Promotes a pro-inflammatory environment and drives PATIENT A: anti-cancer

  40. Slide 40: Appendix: Regulatory

    Appendix Regulatory 40

  41. Slide 41: Significant Progress in 2019

    Significant Progress in 2019 4 Pivotal Face-to-Face Meetings Led to BLA Submission of Clinical/Nonclinical Data May 2019: FDA Accepts CMC Analytical Comparability Plan • No additional clinical trials deemed necessary at this time, subject to final review of comparability data in the BLA June 2019: F

  42. Slide 42: Positive Interactions with EMA on Regulatory Pathway

    Positive Interactions with EMA on Regulatory Pathway for Vicineum May 7, 2020 CHMP clinical advice for Vicineum: • The nonclinical and clinical pharmacology studies, and safety database are all sufficient to support a MAA submission for Vicineum and no additional clinical trials were requested • The

  43. Slide 43: Appendix: Clinical Data

    Appendix Clinical Data 43

  44. Slide 44: Strong benefit-risk profile in Phase III Trial

    Vicineum demonstrates a strong benefit-risk profile in our Phase III Trial Efficacy Surrogate Time to Health Endpoints Cystectomy Outcomes Benefit Risk : Safety and Tolerability Selectively targets cancer cells while generally avoiding healthy cells Favorable profile relative to BCG, Valstar, checkp

  45. Slide 45: Phase III Trial: Patient Demographics

    Phase III Trial: Patient Demographics COHORT 1 COHORT 2 COHORT 3 CHARACTERISTICS CIS that was refractory or CIS that recurred >6 Papillary tumors (without recurred within 6 months CIS) that recurred within of adequate BCG adequate BCG 6 months of adequate BCG Total patients enrolled 86 7 40 Evaluabl

  46. Slide 46: Compelling Clinical Data Set

    Compelling Clinical Data Set Endpoint How Endpoint is Measured Results Complete Response Rate (CRR) • 40% CRR at 3 months Defined as the proportion of patients who show no evidence of high-risk Primary Endpoint • Lower bound of 95% CI rules out clinically unmeaningful CRR disease, or disease progres

  47. Slide 47: Complete and Partial Response in Phase II

    Complete and Partial Response: In our Phase II clinical trial, 83% of patients had a complete or partial response 3-Month Response 40% of patients had a complete response Start of Treatment with 43% of patients had a partial response Vicineum 17% of patients had no response *Note: Data are from Phas

  48. Slide 48: Duration of Response in CIS patients

    Duration of Response: 52% of CIS patients who had a complete response at 3 months remained disease-free for a total of 12 months after starting treatment Median Duration of Response is 287 days (95% CI, 154-NE* days) (9.4 months)** 100 KM Estimate 80 X Censored 95% CI 60 52% 39% 40 % of% Patients wi

  49. Slide 49: Duration of Response by BCG exposure

    Duration of Response: Vicineum is generally more efficacious in CIS patients treated with less BCG The BCG shortage may cause a new normal wherein patients receive less BCG 100 Legend: 7-9 BCG instillations 80 X Censored 60 Median 40 20 % ofPatients with Complete Response 0 3 6 9 12 15 18 21 At time

  50. Slide 50: Probability of remaining cancer-free with longer response

    Duration of Response: The longer you have a complete response, the higher the probability of remaining cancer-free Probability of Maintaining Complete Response (CR) for at Least One Additional Year* CR at 12 months 74% CR at 9 months 61% CR at 6 months 56% CR at 3 months 42% Day 0 17% 0% 20% 40% 60%

  51. Slide 51: Time to Disease Recurrence

    Time to Disease Recurrence: Time to Disease-Recurrence: 50% of high-risk papillary patients who were treated with Vicineum are disease-free at 1 year Median time to recurrence is 402 days per Kaplan-Meier estimate (13.2 months) 100 Legend: 80 KM Estimate X Censored 95% CI 60 50% 40 37% % ofPatients

  52. Slide 52: Highly Differentiated Time-to-Cystectomy Data

    Highly Differentiated Time-to-Cystectomy Data vs. Currently Available Agents 76% of patients are cystectomy-free for 3 years No patient on treatment progressed to metastatic disease 100 Legend: KM Estimate X Censored 80 95% CI 60 Median 40 20 % ofPatients Cystectomy-Free 0 0 3 6 9 12 15 18 21 24 27

  53. Slide 53: Time to Cystectomy: Responders vs non-responders

    Time to Cystectomy: Responders have an 88% probability of remaining cystectomy-free 3 years after starting treatment The average responder remains cystectomy-free for 1,035 days vs. 631 days for non-responders 100 Statistically significant difference for 80 responders vs. non-responders: p = < 0.001

  54. Slide 54: Overall Survival

    Overall Survival 1- and 2-year survival rates of patients on trial are comparable to those of the general population of similar age and gender demographics (predominantly male in their 70s) Survival Estimates Patients on VISTA Trial General Population1 1 year 98% 97% 2 years 96% 94% 1U.S. Social Sec

  55. Slide 55: Additional Vicineum Clinical Data: Phase II vs. Phase III

    Additional Vicineum Clinical Data Preliminary Phase II vs. Phase III Complete Response Rate Time Point Phase II Pooled CRR (95% Confidence Interval) Phase III Pooled CRR (95% Confidence Interval) 3-months 40% (26%-56%) 40% (30%-51%) 6-months 27% (15%-42%) 28% (19%-39%) 9-months 18% (8%-32%) 21% (13%

  56. Slide 56: Evaluable Patient Data Tables by Cohort for CIS

    Phase III Trial: Evaluable Patient Data Tables by Cohort for Carcinoma in situ Cohort 1 (n=82) Complete Response Rate Time Point Evaluable Patients Complete Response Rate (95% Confidence Interval) 3-months n=82 39% (28%-50%) 6-months n=82 26% (17%-36%) 9-months n=82 20% (12%-30%) 12-months n=82 17%

  57. Slide 57: Recurrence-free Rate in papillary patients

    Recurrence-free Rate: 42% of high-risk papillary patients remain disease- free after one year Recurrence-free (RF) Rate (Papillary patients) Time Point Evaluable Patients RF Rate (95% Confidence Interval) 3-months n=38 71% (54%-85%) 6-months n=38 58% (41%-74%) 9-months n=38 45% (29%-62%) 12-months n

  58. Slide 58: Safety and Tolerability

    Safety and Tolerability: Our Phase II and Phase III clinical trials are highly consistent for safety and tolerability Increased dosing and duration of exposure does not appear to lead to an increase in incidence or severity of AEs Phase II Phase III Category Treatment-related serious adverse Patient

  59. Slide 59: No age-related increase in adverse events

    Safety and Tolerability: No age-related increase in adverse events in our Phase III trial The average patient in the VISTA trial was ~74 years old Adverse Events 10 9.0 Treatment-related Adverse Events 7.9 8 7.5 6 4 3.0 2.1 2 1.6 0 54-69 70-79 80+ (n=40) (n=57) (n=36) Age (years) Note: Data consist

  60. Slide 60: High-Level Overview of Planned Confirmatory Trial

    High-Level Overview of Planned Confirmatory Trial Successful in alignment with the FDA on the design of the post-marketing confirmatory trial for Vicineum Key Elements The confirmatory trial will enroll BCG-refractory patients who received less-than-adequate BCG* • This represents a broader patient

  61. Slide 61: Head and Neck Cancer: Difficult-to-Treat

    HEAD AND NECK CANCER: Difficult-to-Treat & Dominated by Primary Tumor • Head and neck cancers affects >650,000 people worldwide; ~350,000 deaths each year1 • 90% are squamous cell carcinomas of the head and neck (SCCHN)1 - Two-thirds diagnosed with advanced disease and severe prognosis • High risk o

  62. Slide 62: Monotherapy Studies in Late-stage SCCHN

    VICINEUMMonotherapy Studies Demonstrate Opportunity in Late-stage SCCHN PHASE 1 TRIALS ASSESSING DAILY AND COMPLETED U. S. PHASE 2 TRIAL WEEKLY DOSES SUGGEST IMMUNE DRIVEN • Weekly administration of 500 µg or 700 µg via RESPONSE intratumoral injection; 700 µg established as RP2D • Anti-tumor activit

  63. Slide 63: Pipeline of Targeted Therapies

    Pipeline of Targeted Therapies We believe there is strong scientific rationale for Vicineum in combination with checkpoint inhibitors. Vicineum in combination with AstraZeneca’s anti-PD-L1, Imfinzi (durvalumab), is being evaluated in a Phase 1 trial run by the National Cancer Institute. PRODUCT CAND

  64. Slide 64: Appendix: Commercial Opportunity

    Appendix Commercial Opportunity 64

  65. Slide 65: Virtuous Cycle of Advocacy

    Virtuous Cycle: High possibility that all three key segments are advocates & take action Physicians (Ancillary HCPs) Patients Payers (Caregivers/ Encourage use of Vicineum before RC (Private/ families) public) Advocate for product reimbursement Sources: Sesen Bio internal market research: Patient Jo

  66. Slide 66: Differentiated vs. branded agents in Urology

    Brand Logo Differentiated vs. branded agents in Urology TM 66

  67. Slide 67: Potential to Provide Continuity of Care for NMIBC

    Vicineum has the Potential to Provide Continuity of Care for Patients with NMIBC Checkpoint Treatment Protocol BCG Vicineum Inhibitors Treatment at Urology office X Directed by Urologist X Administration by Urology nurse X Bladder infusion via urinary catheter X 2-hour infusion, hold, and rotation X

  68. Slide 68: Clinical Data from Emerging Treatments for NMIBC

    Clinical Data from Emerging Treatments for NMIBC Vicineum Profile Keytruda Profile Tecentriq Profile Gen (Phase III Data) (Phase II Data) (Phase II Data) Efficacy N=89 N=102 N=73 Complete Response Rate • At 3 Months 40% (CI: 30-51) 41% (CI: 32-51) 41% (CI: 30-53) • At 12 Months 17% 20% No data repor

  69. Slide 69: 1Q 2020 Market Research Results

    1Q 2020 Market Research Results Reasons Urologists Prefer Vicineum Profile • Urologists strongly prefer to retain ownership of patient journey – High degree of reluctance to refer to Medical Oncologists – Fear of losing follow-up diagnostics with patient after treatment referral • Urologists perceiv

  70. Slide 70: Concentrated Prescriber Base Allows Efficient Commercial Model

    Highly Concentrated Prescriber Base Allowsfor CommercialEfficient Model 1 AUA State of the Urology Workforce and Practice in the United States. 2017. 2017. States. United the in Practice and Workforce Urology the of State AUA 2 Health Verity 2019. Verity Health 1 % of Patients 100% 10% 20% 30% 40% 5

  71. Slide 71: Educating caregivers via digital and social channels

    At treatment decision points, caregivers often play an influential role Our strategy is to educate and inform caregivers via a wide range of digital and social channels Digital • Paid search • Organic search • Videos • Banners • Website (branded or unbranded) Social • Facebook community groups • Twi

  72. Slide 72: Pricing and Reimbursement

    Pricing and Reimbursement US Benchmarks Price Reference Payer Management Responses (Annual Cost) to Pricing2 100% $200K Anticipated Opdivo1 Keytruda1 competitive Tecentriq1 pricing $150K 50% Proportion of Payers $100K 0% $30 K $60 K $90 K $150 K $50K Unrestricted Coverage PA to Label Key: PA to Tria

  73. Slide 73: Competitive Scan

    Competitive Scan Approved/Pipeline Products Second Line Monotherapies Checkpoint Inhibitors: Gene Therapy: Adenovirus Vectors Keytruda Adstiladrin • Approved for NMIBC January 2020 • Missed May PDUFA date • Reimbursed at $175,000/year with minimal payer restrictions • Received a CRL from the FDA in

  74. Slide 74: Sesen Bio OUS Strategy Overview

    Sesen Bio OUS Strategy Overview • Vicineum is a product with potential for registration and reimbursement in multiple developed markets • OUS opportunity for Vicineum is 2-3 times larger than the US • Efficient process to manage strong, engaged relationships with key partners worldwide • Partner wit

  75. Slide 75: Sesen Bio OUS Update

    Sesen Bio OUS Update July 31, 2020: Announced partnership with Qilu Pharmaceutical for the manufacture, development and commercialization of Vicineum in Greater China* • Represents the first of 6-10 anticipated OUS deals • Financial terms include significant sources of non-dilutive capital • Qilu wi

  76. Slide 76: Partnership Opportunity in China: Qilu Pharmaceutical

    Partnership Opportunity in China: Qilu Pharmaceutical Profile • Top 10 Pharmaceutical Company in China with >$3B in annual revenues • Extensive clinical experience • 2nd largest clinical team in Chinese Big Pharma • Focused on biosimilar and innovative drugs, with nearly 40 years of clinical develop

  77. Slide 77: Overview of Qilu License Agreement

    Overview of Qilu License Agreement • Financial terms include significant sources of non-dilutive capital • Upfront payment of $12M in cash • Eligibility to receive up to $23M in regulatory and tech transfer milestones in addition to 12% royalties on net sales for at least 12 years • Qilu will be the

  78. Slide 78: Building Our Reputation as a Partner of Choice

    Building Our Reputation as a Partner of Choice Feedback Received from Qilu During the Negotiation Process Vicineum is a highly differentiated product that addresses a huge unmet need Highly knowledgeable clinical and manufacturing teams Significant CMC capabilities and experience Strong cultural fit

  79. Slide 79: Simulation Inputs: US Market

    Simulation Inputs: US Market Estimated patients eligible for branded therapy1 (Annual high-risk NMIBC patients unresponsive to BCG) Lower Bound Upper Bound 7,800 patients 20,400 patients Estimated peak market share2 (Likely share of branded agents) Lower Bound Upper Bound 20% 75% Approximate year 1

  80. Slide 80: Simulation Inputs: OUS Market

    Simulation Inputs: OUS Market Estimated incidence relative to the US1 Estimated price relative to the US2 (High-risk NMIBC patients unresponsive to BCG) (Anticipated reimbursed price) Lower Bound Upper Bound Lower Bound Upper Bound Europe 1.1 1.3 Europe 0.44 0.84 China 1.6 1.8 China 0.20 0.60 MENA 0

  81. Slide 81: Appendix: Manufacturing & Supply Chain

    Appendix Manufacturing & Supply Chain 81

  82. Slide 82: Reliable and Inexpensive Manufacturing Process

    Reliable and Inexpensive Manufacturing Process • Vicineum is manufactured using a robust, industry-standard microbial expression system • The manufacturing process is highly reliable, reducing the risk of supply shortages • The manufacturing process is inexpensive, leading to a relatively low cost-o

  83. Slide 83: Appendix: Intellectual Property

    Appendix Intellectual Property 83

  84. Slide 84: Vicineum Patent Life

    Vicineum Patent Life Pending Applications Dosing Strategies for Targeting EpCAM positive bladder cancer. If allowed, Stabilized Chimeric Immunoglobulins would expire in 2036 or later. (April 2020 - July 2020) US: 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 2036 Me

Sesen Bio — Q3 2020 Earnings Presentation on 6ix